Monitoring the Sphingolipid de novo Synthesis by Stable-Isotope Labeling and Liquid Chromatography-Mass Spectrometry.
Level 5 - mechanism / opinion, no new human data
In vitro bench study using animal-derived microsomes
PubMed 31632963 · doi:10.3389/fcell.2019.00210
What was done
The authors developed a cell-free assay using rat liver microsomes to track the complete bottom-up synthesis of ceramides in the endoplasmic reticulum. To distinguish newly synthesized sphingolipids from endogenous background species, stable isotope-labeled substrates (palmitate-d3 and L-serine-d3) were introduced. Pathway intermediates (3-ketosphinganine, sphinganine, dihydroceramide, and ceramide) were separated by liquid chromatography and identified by high-resolution tandem mass spectrometry (LC-MS/MS). Proof-of-concept responsiveness was evaluated by altering cofactor supply (such as NADPH) and adding an enzyme inhibitor (fumonisin B1).
What was found
The abstract reports no quantitative values, analytical metrics, or effect sizes. Qualitatively, the stable-isotope-labeled LC-MS/MS method successfully distinguished and tracked sequential intermediates in the de novo sphingolipid synthesis pathway and demonstrated expected changes upon cofactor modulation (NADPH) and targeted enzyme inhibition (fumonisin B1).
Why it matters
This method provides a cell-free platform to monitor the complete ER-associated de novo sphingolipid biosynthetic pathway in a single workflow, offering a tool to screen enzyme inhibitors and study atypical lipid metabolism.
Limits
The assay is an in vitro cell-free model derived from rat liver microsomes, which does not capture intact cell compartmentalization, inter-organelle transport, or human in vivo biology. The abstract provides no quantitative assay validation parameters, such as sensitivity, limits of detection, precision, or recovery.
Cited by
- supports Medium-chain triglycerides (MCTs) do not serve as substrates for ceramide synthesis.